Patents by Inventor Robert A. Kastelein

Robert A. Kastelein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD1 AND/OR LAG3 BINDERS
    Publication number: 20260184783
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: July 3, 2025
    Publication date: July 2, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Edward BOWMAN, Maribel BEAUMONT, Marie-Ange BUYSE, Carlo BOUTTON, Bruno DOMBRECHT, Robert A. KASTELEIN, David VLERICK
  • PD1 and/or LAG3 binders
    Patent number: 12351630
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: July 8, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer
    Patent number: 11918648
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 5, 2024
    Assignees: MERCK SHARP & DOHME LLC, TRISALUS LIFE SCIENCES, INC.
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • NAV1.7 BINDERS
    Publication number: 20240002497
    Abstract: Antibodies and antigen-binding fragments thereof that bind the human voltage-gated sodium channel Nav1.7? protein subunit (Nav1.7 binders) are described. In particular embodiments, the Nav1.7 binders comprise a heavy-chain immunoglobulin single variable domain (ISVD or VHH).
    Type: Application
    Filed: November 18, 2021
    Publication date: January 4, 2024
    Applicants: MERCK SHARP & DOHME LLC, MERCK SHARP & DOHME RESEARCH GMBH
    Inventors: Pravien Damitha Abeywickrema, Erik Depla, Bruno Dombrecht, Daniel M. Gorman, Andrea K. Houghton, Robert A. Kastelein, Richard L. Kraus, John Majercak, Kalyan Pande, Sujata Sharma
  • CTLA4 binders
    Patent number: 11649290
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: May 16, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
  • ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BICPECIFIC ANTIBODIES
    Publication number: 20220251194
    Abstract: Provided herein are treatments of conditions ameliorated by counteracting tumor mediated immune suppression. More specifically, provided herein are anti-PD-1/LAG-3/TIGIT trispecific antibodies, anti-PD-1/LAG3 bispecific antibodies, anti-LAG3 antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 28, 2020
    Publication date: August 11, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Robert A. Kastelein
  • PD1 AND/OR LAG3 BINDERS
    Publication number: 20220041727
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: October 8, 2021
    Publication date: February 10, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • PD1 and/or LAG3 binders
    Patent number: 11168135
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: November 9, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • PD1 and/or LAG3 binders
    Patent number: 11168136
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: November 9, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • PD1 and/or LAG3 binders
    Patent number: 11155619
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: October 26, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist
    Patent number: 11052065
    Abstract: The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein R1 or R2 are as herein defined, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: July 6, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Elaine M Pinheiro, Michael Rosenzweig, Robert A. Kastelein, David R. Kaufman, Deborah A. Law
  • COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20210196819
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: August 21, 2020
    Publication date: July 1, 2021
    Inventors: Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF PROGRAMMED DEATH RECEPTOR (PD-1) ANTIBODIES AND A CXCR2 ANTAGONIST
    Publication number: 20200276153
    Abstract: The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein R1 or R2 are as herein defined, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
    Type: Application
    Filed: September 24, 2018
    Publication date: September 3, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Elaine M Pinheiro, Michael Rosenzweig, Robert A. Kastelein, David R. Kaufman, Deborah A. Law
  • Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
    Patent number: 10751412
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 25, 2020
    Assignees: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • PD1/CTLA4 binders
    Patent number: 10544222
    Abstract: The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 28, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Juha Punnonen, Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, David Vlerick, Robert A. Kastelein
  • CTLA4 binders
    Patent number: 10501542
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Juha Punnonen, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Bjorn Victor, Robert A. Kastelein
  • PD1 AND/OR LAG3 BINDERS
    Publication number: 20190338025
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: May 17, 2019
    Publication date: November 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribal Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • PD1 AND/OR LAG3 BINDERS
    Publication number: 20190330340
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 31, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • PD1 AND/OR LAG3 BINDERS
    Publication number: 20190330339
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 31, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
  • PD1 and/or LAG3 binders
    Patent number: 10323090
    Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 18, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, David Vlerick, Robert A. Kastelein